Contestación del Capítulo de Cirugía Endovascular al Editorial publicado en Cir Cardiov. 2017;24(2):53-55 por el Dr. Juffé y el Dr. Hornero, en el que exponen su opinión sobre el tratamiento endovascular en la Cirugía Cardiaca.

Contestación CCEV:
Descargar pdf

Convocatoria Reuniones C-CEV en el Congreso de Valladolid 2017

Convocatoria Comité Científico:
Descargar pdf

Convocatoria Asamblea General Ordinaria:
Descargar pdf

Convocatoria Reunion de la Junta Directiva C-CEV:
Descargar pdf

 

Celebrado con éxito rotundo de participación y nivel científico el V Simposium del Capítulo de Cirugía Endovascular de la Sociedad Española de Angiología y Cirugía Vascular

25 inscripciones gratuitas cedidas por el Prof. Dr. Michael Jacobs para el European Vascular Course 2017. 

Se abre un plazo hasta el Simposium de Madrid del CCEV para presentar las solicitudes via email (secretarioCCEV@seacv.es). El único requisito es
ser miembro del CCEV.

Información:
EVC 2017
Program EVC 2017

July 14, 2016—MicroVention, Inc., a wholly owned subsidiary of Tokyo-based Terumo Corporation, announced that Terumo Corporation has completed the acquisition of Sequent Medical, Inc., a privately held medical device… Leer noticia completa

July 13, 2016—Medtronic plc announced US Food and Drug Administration (FDA) approval for the In.Pact Admiral drug-coated balloon (DCB) in longer, 150-mm lengths. The new 150-mm-length balloon, available in diameters of 4, 5, and 6 mm,… Leer noticia completa

July 13, 2016—Vascular Insights, LLC announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has recently issued Interventional Procedure Guidance IPG557, approving endovenous mechanochemical ablation for the treatment of… Leer noticia completa

July 8, 2016—Essential Medical, Inc. announced that it has received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to begin the United States clinical trial for Manta, the… Leer noticia completa

SVS Seeks Reconsideration of CMS’s Proposed Rule Changes Related to MACRA

uly 12, 2016—Sirtex Medical Ltd announced the presentation of new data that suggest that patients with liver-dominant metastatic colorectal cancer (mCRC) who underwent first-line treatment with mFOLFOX6 and SIR-Spheres yttrium-90 (Y-90)… Leer noticia completa